Hi,
As many of you know, I am alive today because of my entering two phase I clinical trials, one for PCI-32765 that later became known as ibrutinib and another for a CAR-T drug.
Clinical trials are always great, right?
Well Dr. Furman has a more nuanced answer to that from our interview at ASH 2018. And he is clearly putting the patient first.
No-one is saying that clinical trials are not the best source of evidence, but what questions are being answered and at what cost to patients need to be carefully considered.
See: https://cllsociety.org/2019/01/ash-2018-dr-furman-on-the-evolving-role-of-clinical-trials-in-cll/ for the interview.
Lots more news on the website. Hard to keep up
And please don’t forget to register our upcoming educational forums in Duarte, Charlotte, Seattle, Portland and Houston in the next 60 days.
Stay strong.
We are all in this together.
Brian
Cllsociety.orgIf you want a personal response, or just want to stay in touch, please email me at [email protected]. I have no other way of contacting. Thanks. Stay strong. After all, we are all in this together. And please visit our website: http://cllsociety.org for the latest news and information.
Community Magazine
Author's Latest Articles
-
A Matching-Adjusted Indirect Comparison of Acalabrutinib Vs. Zanubrutinib in Relapsed Or Refractory CLL
-
My Personal Decision to Restart My CLL (chronic Lymphocytic Leukemia) Treatment
-
ASH 2022: Adverse Events from BTK Inhibitors in Clinical Trials
-
Dr. Stephan Stilgenbauer on the Evolution of CLL to Richter’s Syndrome from ASH 2022